TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04196933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temporal Binding Adaptation - PSS adaptation with VI stimulation
Description: The adaptation will utilize the same approach used in non-implanted patients. The investigators will provide a repeated, fixed SOA with either the CI or VI leading the other stimulus by 220 ms. After the training period, which will match the number of stimuli pairs provided to our normal vestibular-auditory control subjects undergoing PSS adaptation, the TOJ study is repeated to recalculate the PSS and TBW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Motion-modulated Stimulation
Description: To provide 8 hours of 'physiologic' CI and VI inputs during normal activities, the investigators will employ standard motion-modulated stimulation with the VI. This requires pre-adaptation to a 200 pps tonic stimulation rate (to emulate the push-pull design of the native vestibular system allowing modulating stimulation upward or downward with opposite directions of motion). The three electrodes are connected to the head-mounted prosthetic circuit, which consists of three angular velocity sensors (one aligned with the sensitive axis of each canal) such that head rotations in the plane of the given canal modulate the stimulation rate of the corresponding electrode, upward (for ipsi) or downward (for contralateral) head rotations, thereby simulating normal canal-mediated modulations.
Study: NCT03752502

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
Study: NCT01365182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BF+SUPPORT
Description: A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BF+PHONE
Description: A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
Study: NCT03918356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical impedance myography
Description: Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical impedance myography
Description: Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: healthy control group
Description: healthy control
Study: NCT02075580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological support (interactive/cognitive strategies)
Description: * cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~* metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~* psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~* questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)
Study: NCT01909492

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Patients will provide a serum sample for research.
Study: NCT02227199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00733681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFC Sigma RP TC3 Revision knee system
Description: Orthopaedic implant system for revision total knee replacement
Study: NCT02188654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg/day retarded formulation of metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg/day of placebo tablets
Study: NCT01764828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT04369950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:200,000 epinephrine and epidural morphine
Description: Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% 2-chloroprocaine and epidural morphine
Description: Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
Study: NCT01086371

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic auditory stimulation
Description: Recorded music with embedded beat set 10% above the subject's baseline walking cadence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation
Description: Recorded music with embedded beat set 10% above the subject's baseline walking cadence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise
Description: Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
Study: NCT02397148

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: imagery with ionizing radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography
Description: imagery with ionizing radiation
Study: NCT06426836

Intervention type: OTHER
Group type: OTHER
Intervention: Amoxicillin-clavulanate
Description: blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care

Intervention type: OTHER
Group type: OTHER
Intervention: Piperacillin-tazobactam
Description: blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.

Intervention type: OTHER
Group type: OTHER
Intervention: Meropenem
Description: blood sampling in patients receiving meropenem as part of routine clinical care.

Intervention type: OTHER
Group type: OTHER
Intervention: Cefazolin
Description: blood sampling in patients receiving cefazolin as part of routine clinical care.

Intervention type: OTHER
Group type: OTHER
Intervention: Vancomycin
Description: blood sampling in patients receiving vancomycin as part of routine clinical care.

Intervention type: OTHER
Group type: OTHER
Intervention: Teicoplanin
Description: blood sampling in patients receiving teicoplanin as part of routine clinical care.

Intervention type: OTHER
Group type: OTHER
Intervention: Ciprofloxacin
Description: blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.

Intervention type: OTHER
Group type: OTHER
Intervention: Amikacin
Description: blood sampling in patients receiving amikacin as part of routine clinical care.
Study: NCT01083589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Oral 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
Study: NCT04988009

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical chart

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT01891474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-health care
Description: voice inception technique based U-healthcare service
Study: NCT03893682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-806
Description: CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
Study: NCT04302545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoinflation
Description: Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
Study: NCT01691040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-H94
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: intravenous injection
Study: NCT03424460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemostasis tests
Description: Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemostasis tests
Description: Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemostasis tests
Description: Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monocytes and megacaryocytes culture and RNA extraction
Description: Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monocytes and megacaryocytes culture and RNA extraction
Description: Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monocytes and megacaryocytes culture and RNA extraction
Description: Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA extraction
Description: RNA extraction from liver tissue

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: RNA extraction
Description: RNA extraction from liver tissue
Study: NCT03922178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure/Volume Combination Catheter
Description: Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiogram
Description: A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
Study: NCT03860363

Intervention type: DEVICE
Intervention: Blood drainage post cardiac surgery
Description: Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
Study: NCT03696901

Intervention type: DRUG
Intervention: Xydalba
Description: Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
Study: NCT01636349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soccer exercise or continued daily lifestyle
Description: Recreational soccer or continued unchanged lifestyle
Study: NCT01209221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - MAD
Description: Once or twice daily doses of matching placebo to RO5271983 for 14 days
Study: NCT04012788

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo powder
Study: NCT04635917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized diet
Description: Participants in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting these dietary goals, participants will be provided with nuts, fruits, and vegetables.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized diet
Description: Participants in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting these dietary goals, participants will be provided with nuts, fruits, and vegetables.
Study: NCT01209221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SAD
Description: Single dose of matching placebo to RO5271983 for up to 3 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5271983 - MAD
Description: Once or twice daily doses of RO5271983 for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5271983 - SAD
Description: Single dose of RO5271983 at each period (for up to 3 periods)
Study: NCT03402009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Apps
Description: Apps and weblinks to coach self-guided meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apps
Description: Apps and weblinks to coach self-guided meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EEG neurofeedback
Description: Device provides feedback based on EEG readings.
Study: NCT02313025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech sound intervention
Description: An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: World-project
Description: An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
Study: NCT02417051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disaster Worker Resiliency Training
Description: The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
Study: NCT03265249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRIDGE device
Description: an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
Study: NCT04623918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron-biofortified rice
Description: Iron-biofortified rice (IR68144-2B-2-2-3)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control rice
Description: Control rice (C4), identical in appearance
Study: NCT04309656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered.
Study: NCT00935870

Intervention type: DEVICE
Intervention: Bioactive glass and/or autogenous bone
Description: No intervention in the current study (10-year follow-up study)
Study: NCT01909492

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Patients will provide a serum sample for research.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Patients will provide a serum sample for research.
Study: NCT00935870

Intervention type: DEVICE
Intervention: Bioactive glass and/or autogenous bone
Description: No intervention in the current study (10-year follow-up study)

Intervention type: DEVICE
Intervention: Bioactive glass and/or autogenous bone
Description: No intervention in the current study (10-year follow-up study)
Study: NCT01277523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium high dose
Description: 2 actuations once daily
Study: NCT01909492

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Patients will have a lumbar puncture to obtain CSF.

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Patients will have a lumbar puncture to obtain CSF.

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Patients will have a lumbar puncture to obtain CSF.
Study: NCT03431246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil and Gardasil-9
Description: All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
Study: NCT01277523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 actuations once daily
Study: NCT01598831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART-123
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
Study: NCT05151952

Intervention type: RADIATION
Intervention: Other: Registry
Description: Registry of cancer patients who receive proton radiation therapy.
Study: NCT02837874

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isoperistaltic
Description: Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antiperistaltic
Description: Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
Study: NCT02089165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill meal
Description: Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
Study: NCT03497975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER Tablets
Description: Active Nalbuphine ER Tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablets
Description: Matching Tablets with no active substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER Tablets
Description: Open Label Extension